• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Adial Pharmaceuticals, Inc (Amendment)

    8/18/21 6:03:16 AM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADIL alert in real time by email
    SC 13G/A 1 sc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)

     

      Adial Pharmaceuticals, Inc.  
      (Name of Issuer)  
         
      Common Stock, par value $0.001 per share  
      (Title of Class of Securities)  
         
      00688A106  
      (CUSIP Number)  
         
      August 17, 2021  
      (Date of Event Which Requires Filing of This Statement)  

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      [  ] Rule 13d-1(b)
      [X] Rule 13d-1(c)
      [  ] Rule 13d-1(d)

     

     

     

     
     


     

     

    CUSIP No. 00688A106

     

       

     

    1

    NAME OF REPORTING PERSONS

    S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Mark Howard Peikin

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

    (a) [  ]

    (b) [  ]

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER

    OF
    SHARES

    BENEFICIALLY

    OWNED
    BY

    EACH

    REPORTING

    PERSON
    WITH

    5

    SOLE VOTING POWER

     

    1,346,741 (1)

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    1,346,741 (1)

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,346,741 (1)

     

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    6.67% (Based upon 20,448,156 outstanding shares of common stock as of August 17, 2021)

     

    12

    TYPE OF REPORTING PERSON*

     

    IN

     

     
     

     

     

    CUSIP No. 00688A106

     

     

     

    Item 1(a). Name of Issuer:

     

    This Amendment No. 1 amend the statement on Schedule 13G filed on August 13, 2021, with respect to Common Stock, $0.001 par value, of Adial Pharmaceuticals, Inc. (the “Issuer”).

     

    Item 1(b). Address of Issuer’s Principal Executive Offices:

     

    1180 Seminole Trail, Suite 495

    Charlottesville, Virginia 29902

    United States of America

     

    Item 2(a). Name of Person Filing.

     

    Mark Howard Peikin.

     

    Item 2(b). Address of Principal Business Office or, if None, Residence.

     

    1875 N.W. Corporate Blvd., Ste 290, Boca Raton, FL 33431.

     

    Item 2(c). Citizenship.

     

    United States.

     

    Item 2(d). Title of Class of Securities.

     

    Common stock, par value $0.001 per share.

     

    Item 2(e). CUSIP Number.

     

    00688A106

     

    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    Item 4. Ownership.

     

      (a) Amount beneficially owned: 1,346,741 (1)
      (b) Percent of class: 6.67%
      (c) Number of shares as to which the Reporting Person has:

     

      (i) Sole power to vote or to direct the vote: 1,346,741(1)
      (ii) Shared power to vote or to direct the vote: 0
      (iii) Sole power to dispose or to direct the disposition of: 1,346,741 (1)
      (iv) Shared power to dispose or to direct the disposition of: 0
       
    (1)Mark Howard Peikin is the beneficial owner of Bespoke Growth Partners, Inc. and has the power to vote and dispose of the 833,334 shares of the Issuer held by Bespoke Growth Partners, Inc. Further, Mark Howard Peikin is the beneficial owner of First Choice International Company, Inc. and has the power to vote and dispose of the 150,000 shares of the Issuer held by First Choice International Company, Inc. Additionally, Mark Howard Peikin beneficially owns 363,407 shares of the Issuer directly in his own name, and he has the power to vote and dispose of such shares.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported by the Parent Holding Company.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. 

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: August 18, 2021 By: /s/ Mark Howard Peikin
        Mark Howard Peikin

     

     

    Get the next $ADIL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADIL

    DatePrice TargetRatingAnalyst
    11/14/2024$8.00Buy
    Rodman & Renshaw
    10/13/2021$12.00Buy
    Brookline Capital
    6/29/2021$5.00Buy
    Litchfield Hills
    More analyst ratings

    $ADIL
    Leadership Updates

    Live Leadership Updates

    See more
    • Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update

      GLEN ALLEN, Va., March 04, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2024 fiscal year ended December 31, 2024. Key Highlights Successful completion of AD04-103 pharmacokinetics (PK) study of AD04, corroborating bioavailability, dose proportionality, no food effect, and safety profile consistent with the use of Ondansetron. Advancement towards pivotal Phase 3 trial design supportive of ongoing partnership

      3/4/25 8:30:00 AM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

      GLEN ALLEN, Va., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the third quarter of 2024. Cary Claiborne, President and Chief Executive Officer of Adial, stated, "We reached an important milestone this quarter with the successful database lock of the pharmacokinetics study for AD04, our lead investigational, genetically targeted therapeutic for the treatment of Alcohol Use Disorder (AUD). The pharmacokinetics study is e

      11/13/24 8:30:00 AM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

      GLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Vinay Shah as the Company's Chief Financial Officer, effective November 16, 2024. Vinay Shah is an accomplished Chief Financial Officer with over 25 years of experience in the pharmaceutical, biopharmaceutical, and healthcare sectors, specializing in financial strategy, investor relations, and operational efficiency. Most recently, Mr. Shah served as the CFO at Virpax Pharmaceuticals, Inc. (N

      11/5/24 8:30:00 AM ET
      $ADIL
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADIL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Adial Pharmaceuticals with a new price target

      Rodman & Renshaw initiated coverage of Adial Pharmaceuticals with a rating of Buy and set a new price target of $8.00

      11/14/24 7:21:37 AM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Brookline Capital initiated coverage on Adial Pharmaceuticals with a new price target

      Brookline Capital initiated coverage of Adial Pharmaceuticals with a rating of Buy and set a new price target of $12.00

      10/13/21 11:54:22 AM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Litchfield Hills initiated coverage on Adial Pharmaceuticals with a new price target

      Litchfield Hills initiated coverage of Adial Pharmaceuticals with a rating of Buy and set a new price target of $5.00

      6/29/21 10:47:45 AM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADIL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration

      Meeting to Take Place on July 25, 2025 Meeting's Purpose is To Discuss Upcoming Clinical Development Plan and Protocol Designs GLEN ALLEN, Va., May 08, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that the FDA has granted Adial's request for an End of Phase 2 meeting to discuss Adial's proposed clinical development plan and seek FDA guidance on the Phase 3 adaptive with enrichment design of the upcoming clinical trial for AD04. The meeting will take place on July 25, 2025. AD04 is

      5/8/25 8:30:00 AM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

      GLEN ALLEN, Va., May 02, 2025 (GLOBE NEWSWIRE) --  Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced its entry into a warrant inducement agreement with an existing healthcare-focused institutional investor of the Company for the immediate exercise of existing Series B Warrants (the "Series B Warrants") to purchase up to 1,418,440 shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), and Series C Warrants (the "Series C Warrants", and together with the Series B Warrants the "Existi

      5/2/25 11:48:51 AM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders

      GLEN ALLEN, Va., May 01, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 12,274,692 was issued on April 15, 2025 by the United States Patent and Trademark Office (USPTO) covering a novel method of treating alcohol-related diseases and opioid-related disorders using AD04 in genetically identified patients. This newly issued patent strengthens Adial's intellectual property portfolio by covering the administration of AD04, the Company's investigational drug, as a precision

      5/1/25 8:30:00 AM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADIL
    Financials

    Live finance-specific insights

    See more
    • Adial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use Disorder

      Company to pursue path toward U.S. and European approvals; Type C meeting with FDA confirmed for Q2 2023; plans in place to meet with multiple European regulatory authorities Adial in discussions with potential pharma partners Conference call to be held at 8:15 a.m. EST tomorrow CHARLOTTESVILLE, Va., March 06, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company") a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided an update on its regulatory strategy for AD04, the Company's lead compound for the treatment of Alcohol Use Disorder (A

      3/6/23 4:19:07 PM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adial Pharmaceuticals Schedules Business Update Conference Call

      CHARLOTTESVILLE, Va., March 02, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will host a conference call and webcast on Tuesday, March 7, 2023, at 8:15 a.m. Eastern Time, to provide an update on its regulatory and partnering strategy for the United States and Europe. The company will also present and discuss the findings from its subgroup analysis of ONWARD data. A live audio webcast of the conference call and accompanying slide presentation may be accessed at https

      3/2/23 9:00:00 AM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adial Pharmaceuticals Announces Topline Results For Onward™ Phase 3 Trial for AD04 in Patients with Alcohol Use Disorder

      AD04 achieved statistically significant mean reduction in heavy drinking days among pre-specified group of heavy drinkers, compared to placebo, with an approximately 79% reduction from baseline drinking AD04 demonstrated statistically significant difference in AUD severity, as compared to placebo, with an 84% decrease in the number of heavy drinking patients meeting the criteria for AUD diagnosis Company plans to submit ONWARD results to both European and U.S. regulatory agencies Conference call to be held today at 1:00 p.m. Eastern Time CHARLOTTESVILLE, Va., July 20, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-sta

      7/20/22 7:00:00 AM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADIL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Adial Pharmaceuticals Inc

      SC 13G/A - ADIAL PHARMACEUTICALS, INC. (0001513525) (Subject)

      11/14/24 3:44:01 PM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Adial Pharmaceuticals Inc

      SC 13G - ADIAL PHARMACEUTICALS, INC. (0001513525) (Subject)

      2/14/24 3:22:13 PM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Adial Pharmaceuticals Inc (Amendment)

      SC 13G/A - ADIAL PHARMACEUTICALS, INC. (0001513525) (Subject)

      2/14/22 5:24:55 PM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADIL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ADIL
    SEC Filings

    See more
    • SEC Form 4 filed by Chief Executive Officer Claiborne Cary J

      4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)

      12/5/24 5:47:13 PM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Shah Vinay

      4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)

      11/18/24 4:01:06 PM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Shah Vinay

      3 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)

      11/18/24 4:00:03 PM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adial Pharmaceuticals Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

      8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)

      5/7/25 5:18:13 PM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Adial Pharmaceuticals Inc

      424B5 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)

      5/2/25 1:46:02 PM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Adial Pharmaceuticals Inc

      424B5 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)

      5/2/25 1:44:28 PM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADIL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Schuyler Kevin bought $1,918 worth of shares (700 units at $2.74) (SEC Form 4)

      4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)

      10/3/23 8:54:38 AM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care